Generic Raldesy Availability
Last updated on Apr 10, 2025.
Raldesy is a brand name of trazodone, approved by the FDA in the following formulation(s):
RALDESY (trazodone hydrochloride - solution;oral)
-
Manufacturer: KAMAT
Approval date: November 26, 2024
Strength(s): 10MG/ML [RLD]
Is there a generic version of Raldesy available?
No. There is currently no therapeutically equivalent version of Raldesy available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Raldesy. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Trazodone and trazodone hydrochloride in purified form
Patent 8,133,893
Issued: March 13, 2012
Inventor(s): Marchetti Marcello & Iacoangeli Tommaso & Ciottoli Giovanni Battista & Biondi Giuseppe
Assignee(s): Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.A process of production of trazodone or trazodone hydrochloride that comprises the steps of: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
Patent expiration dates:
- March 13, 2029✓✓
- March 13, 2029
More about Raldesy (trazodone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- Drug class: phenylpiperazine antidepressants
- Breastfeeding
Patient resources
Other brands
Desyrel, Oleptro, Desyrel Dividose
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.